Research Article

Does Obesity Predispose Medical Intensive Care Unit Patients to Venous Thromboembolism despite Prophylaxis? A Retrospective Chart Review

Bradley J. Peters, Ross A. Dierkhising, and Kristin C. Mara

Mayo Clinic, Rochester, MN, USA

Correspondence should be addressed to Bradley J. Peters; peters.bradley@mayo.edu

Received 2 August 2016; Accepted 26 October 2016

Academic Editor: Timothy E. Albertson

Copyright © 2016 Bradley J. Peters et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Obesity is a significant issue in the critically ill population. There is little evidence directing the dosing of venous thromboembolism (VTE) prophylaxis within this population. We aimed to determine whether obesity predisposes medical intensive care unit patients to venous thromboembolism despite standard chemoprophylaxis with 5000 international units of subcutaneous heparin three times daily. Results. We found a 60% increased risk of venous thromboembolism in the body mass index (BMI) ≥ 30 kg/m² group compared to the BMI < 30 kg/m² group; however, this difference did not reach statistical significance. After further utilizing our risk model, neither obesity nor mechanical ventilation reached statistical significance; however, vasopressor administration was associated with a threefold risk. Conclusions. We can conclude that obesity did increase the rate of VTE, but not to a statistically significant level in this single center medical intensive care unit population.

1. Introduction

Obesity is a significant issue in the United States with nearly 2/3rds of the population considered to be overweight or obese and 1 in 20 adults are considered extremely obese (BMI >40 kg/m²) [1]. Since the 1960s, the prevalence has doubled, but in the past 10+ years this has stabilized [2]. Globally, obesity has doubled since 1980 with 12% of the global population considered obese [3]. In our own institution, intensive care unit (ICU) patients presenting with a BMI >35 kg/m² have increased every year during a 10-year period and these patients now account for over 20% of our medical ICU population. Obesity can alter many of the aspects involved in the care of these patients, from diagnostics and monitoring to medication pharmacokinetics and dosing [4]. As critical care providers, we are often in a position of extrapolating data from a standardized population and applying it to our patients. Often these standardized populations exclude or have minimal subjects in the extremes of body weight. Evidence is increasing in the care of obese patients and it is becoming more evident that obesity is going to be a common comorbidity in the general population. Much of the evidence with regard to medication variables and dosing is related to antimicrobial dosing. There is less evidence directing our interventions to prevent VTE in the medical intensive care unit (MICU) patient. In fact, the last two editions of the Antithrombotic Therapy and Prevention of Thrombosis Guidelines mention obesity as a risk factor for VTE, however leaving no recommendations regarding altered or standard chemoprophylactic dosing regimens to prevent VTE [5–7].

What is known is that critical illness alone can increase the incidence of VTE compared to a non-MICU hospitalized patient [8]. VTE is an important complication of critical illness in that it is often unrecognized while leading to sudden episodes of hypotension, bradycardia, and hypoxia, in addition to problems weaning from respiratory assistance in the case of pulmonary embolism (PE) [8]. Without VTE chemoprophylaxis, the incidence of VTE ranges from 20 to 40% in the critically ill patient population [9–13]. In 2005, Cook et al. found a 10% incidence of VTE in a medical and surgical population after 3 days with surveillance ultrasounds and a BMI of 27.1 (± 7) despite twice daily subcutaneous heparin [8]. Further evidence within mixed medical and
surgical intensive care unit populations suggests potentially inadequate VTE protection with standard chemoprophylaxis dosing of subcutaneous heparin and low molecular weight heparins (LMWH) [14–17] when looking at antifactor Xa activity, although there is no established standard efficacy level.

Extrapolating data from the bariatric surgery population would seem to be a reasonable next step. Upon review of these data, there is some difficulty extrapolating from this population for the purposes of critical care as these patients are often under significantly less inflammatory stress (e.g., sepsis) and are mobilized earlier than a standard medical critical care patient. Additionally, the evidence from these trials ranges from conclusions suggesting no chemoprophylaxis is needed with early mobilization and mechanical devices to altered subcutaneous heparin and LMWH regimens being superior to standard dosing [18–26]. Given the relative lack of specific evidence based VTE chemoprophylactic dosing recommendation in a MICU population, we undertook an evaluation of our subcutaneous heparin prophylactic dosing.

2. Materials and Methods

We performed a single center retrospective chart review of a MICU patient population with the purpose of determining whether there is a difference in the prevalence of VTE found in patients with a BMI <30 kg/m² and a BMI ≥30 kg/m² while receiving (or up to 8 hours after) standard VTE chemoprophylaxis. The study was reviewed and approved by the Institutional Review Board. Inclusion criteria included the first hospitalization of all MICU patients admitted to a medical ICU aged 18 years or older who stayed in the ICU for at least 48 hours and were started on subcutaneous heparin 5000 international units three times daily (SQH) or dalteparin 5000 international units subcutaneously for at least 48 consecutive hours. Of note, there was a formulary change for our institution’s LMWH of choice from dalteparin to enoxaparin during this time frame data; however, due to minimal use of either dalteparin or enoxaparin, this is unlikely to have affected the results. Patients were excluded if they met any of the following criteria: being pregnant and having active therapeutic treatment for confirmed or suspected VTE (warfarin, LMWH, heparin, fondaparinux, and direct thrombin inhibitors), with disease states requiring anticoagulation; history of heparin induced thrombocytopenia (HIT); or arterial thrombosis. Patients were included in the setting of atrial fibrillation so long as they were not receiving therapeutic anticoagulation. Patients were included in situations when acute coronary syndrome, pulmonary embolism, or deep vein thrombosis was in the admission differential and therapeutic anticoagulation was active until these conditions were ruled out. However, their time on therapeutic anticoagulation was not included in the data.

Our primary outcome was the rate of VTE in patients with a BMI <30 kg/m² and patients with a BMI ≥30 kg/m² while on standard VTE chemoprophylaxis. We tested for a null hypothesis of no difference in the rate of VTE between patients with a BMI <30 kg/m² and patients with a BMI ≥30 kg/m². Secondly, we assessed VTE risk factors and characterized the patients who had a VTE.

For baseline characteristics, means and standard deviations were calculated for continuous data, and t-tests were used to compare obesity groups. Frequencies and percentages were computed for nominal data and Pearson’s chi-square or Fisher’s exact test were used as appropriate to compare obesity groups. For the primary outcome of VTE, follow-up started at subcutaneous heparin initiation and ended at 8 hours after heparin ended. A Cox proportional hazards model was constructed to compare obese to nonobese patients. A multivariable Cox proportional hazards model was also used to control for variables potentially associated with the occurrence of a VTE. Thirty patients were observed with a VTE, which allowed us to detect a minimum hazard ratio (HR) of 2.8 between the obesity groups with 80% power using a two-sided, alpha = 0.05 test, assuming equal group sizes.

3. Results

In total, 834 hospitalizations were reviewed with admission dates ranging from July 1, 2010, to July 27, 2013. After exclusion criteria were applied, 273 hospitalizations were excluded, leaving 561 patients for evaluation. Exclusion criteria are shown in Figure 1. At baseline, the groups were similar except that there was a higher percentage of males and those on a mechanical VTE prophylaxis device in the BMI <30 kg/m² group. The higher mechanical VTE prophylaxis device rate is likely associated with issues of placing these devices on patients at the extremes of body habitus. More patients were admitted with a diagnosis of sepsis in the ≥30 kg/m² group. Additionally, the ≥30 kg/m² group had a higher percentage of patients utilizing antiplatelet agents and with documented obstructive sleep apnea (OSA). Baseline characteristics are shown in Table 1. There was no difference in the percentage of patients who received noninvasive, invasive, or a combination of the modes of ventilation. The BMI distribution was primarily in the 25–35 kg/m² range. BMI distribution is shown in Figure 2. In the <30 kg/m² BMI group, nearly 90% of the patients had a BMI 20–30 kg/m² and in the ≥30 kg/m² BMI group one-third of the patients had a BMI >40 kg/m².

The primary outcome of venous thromboembolism occurred during follow-up in 12 patients in the BMI <30 kg/m² group versus 18 patients in the BMI ≥30 kg/m² group. The unadjusted VTE HR comparing the obese to nonobese patients was 1.596 (p = 0.22, CI (confidence interval) 0.75–3.38). Outcomes are listed in Table 2. With 30 events, we fit a multivariable model with 3 variables: obesity, mechanical ventilation, and vasopressors. Risk factors for VTE are listed in Table 3. Obesity and mechanical ventilation were not statistically significant (resp., HR = 1.49, p = 0.2971, CI 0.7022–3.180; HR = 1.06, p = 0.9164, CI 0.3647–3.074). Vasopressor use had a HR 3.037 (p = 0.0316, CI 1.1028–8.364) suggesting a tripling of risk. A VTE was more likely to happen within the first 7 days for the higher BMI group. Kaplan-Meier (KM) curve is shown in Figure 3. The BMI <30 kg/m² group had all observed events occurring within 17
days of taking heparin, with an incidence of 2.2% in the first 7 days. In comparison, VTE events for the BMI $\geq 30$ kg/m$^2$ or greater group all occurred within 20 days with an incidence of 5.8% in the first 7 days. Most of the observed VTE events happened in the ICU setting (24/30) and a majority of the VTE events were DVTs (21/30). There was no difference in the rate of bleeding during hospitalization with 27 events in the BMI $< 30$ kg/m$^2$ group versus 26 events in the BMI $\geq 30$ kg/m$^2$ group (HR = 1.074, $p = 0.8031$, CI 0.612–1.887). Sixty deaths occurred during the hospitalization in the BMI $< 30$ kg/m$^2$ group, versus 37 in the BMI $\geq 30$ kg/m$^2$ group.

4. Discussion

Despite finding an approximately 60% increase risk of VTE in medical ICU patients with a BMI $\geq 30$ kg/m$^2$ compared to a BMI $< 30$ kg/m$^2$ with VTE chemoprophylaxis, this did not reach statistical significance. Due to the low incidence of VTE events, only 3 covariates could be used in our risk model. From this model, obesity and mechanical ventilation were still not statistically significant; however, the use of vasopressors was associated with a threefold increased risk. This appears to be consistent with findings in prior VTE chemoprophylactic literature in other populations, suggesting vasopressors alter the absorption and distribution of a subcutaneously administered product [8, 27].

Looking at the characteristics of patients who developed VTE during follow-up, we noticed that events were grouped around the middle range of BMI (25–35 kg/m$^2$). Characteristics of VTE are listed in Table 4. Proportionally, there were fewer males with an observed VTE event in the BMI $\geq 30$ kg/m$^2$ group but they were similar in age. The majority of patients had a respiratory process driving their reason for admission and this could be expected as our MICU is primarily run by critical care pulmonologists and there are separate neurologic and cardiovascular ICUs. The acute physiology score (APS) is similar between the groups suggesting minimal differences in severity of illness. Most of the patients were on a vasopressor at some point in the ICU stay, but 2 patients in the BMI $< 30$ kg/m$^2$ group were on vasopressors at the time of the event. In the BMI $\geq 30$ kg/m$^2$ group, 3 patients were on active vasopressors at the time of the event. Proportionally, more patients in the BMI $\geq 30$ kg/m$^2$ group had a prior diagnosis of OSA or active hematologic or oncologic malignancy. None of the patients who had an observed VTE event were chronic dialysis patients. More patients in the BMI $\geq 30$ kg/m$^2$ group had a prior diagnosis of OSA or active hematologic or oncologic malignancy. None of the patients who had an observed VTE event were chronic dialysis patients. More patients in the BMI $\geq 30$ kg/m$^2$ group were on an antiplatelet agent, which should have some additional protective effect against thrombosis. Due to the low event rate, this was not included in our risk model; however, in assessing the characteristics of patients who developed a VTE, antiplatelet agents were present in a quarter of the BMI $< 30$ kg/m$^2$ group and a third of the BMI $\geq 30$ kg/m$^2$ group suggesting that antiplatelet agents would likely not alter our results significantly. Heparin induced thrombocytopenia was found in 2 patients in each group.

A recent evaluation explored the preventability of VTE [28]. According to these data, there are VTE events that are unlikely to be preventable. These are primarily associated with catheter-associated deep vein thrombosis (DVT). When looking at our data, during follow-up, the BMI $< 30$ kg/m$^2$ group had 6 catheter-associated DVTs and the BMI $\geq 30$ kg/m$^2$ group had 3 catheter-associated DVTs. Based on Haut's definition of an unpreventable DVT, half of the VTE events in the lower BMI group were not preventable, whereas only a sixth of the events in the higher BMI group would be considered not preventable. This information points at a more significant effect of obesity if nonpreventable VTE could be removed from the results.

In a recent analysis of thrombosis predictors in a randomized thromboprophylaxis trial enrolling patients with elevated BMI, with a family or personal history of VTE, those receiving vasopressors were at the greatest risk [27]. The increased risk of VTE with vasopressors was similar to
Table 1: Baseline demographics.

|                        | BMI < 30 kg/m² | BMI ≥ 30 kg/m² | p    |
|------------------------|---------------|---------------|------|
| Male (%)               | 159 (56%)     | 126 (46%)     | 0.016|
| Average BMI (SD), kg/m²| 24.8 (3.3)    | 38.8 (8.8)    | 0.074|
| Age (SD)               | 61.8 (16.9)   | 64.2 (14.2)   |      |
| Primary reason for admission |            |               | 0.014|
| Cardiovascular         | 22 (7.7%)     | 14 (5.1%)     |      |
| Respiratory            | 151 (53%)     | 133 (48%)     |      |
| Gastrointestinal       | 10 (3.5%)     | 19 (6.9%)     |      |
| Renal                  | 7 (2.5%)      | 11 (4%)       |      |
| Neurologic             | 19 (6.7%)     | 8 (2.9%)      |      |
| Sepsis                 | 50 (17.5%)    | 74 (26.8%)    |      |
| Metabolic              | 6 (2.1%)      | 5 (2%)        |      |
| Other                  | 20 (7%)       | 12 (4.3%)     |      |
| Active hematologic or oncologic process | 50 (17.5%) | 35 (12.7%) | 0.108|
| Documented sleep apnea | 20 (7%)       | 85 (30.8%)    | <0.001|
| History of thrombosis | 15 (5.3%)     | 20 (7.2%)     | 0.332|
| Treatment of thrombosis| 15 (100%)    | 19 (95%)      |      |
| Antiplatelet agents    |               |               | 0.0021|
| Aspirin                | 89 (31.2%)    | 119 (43%)     |      |
| Clopidogrel            | 1 (0.5%)      | 4 (1.5%)      |      |
| Both                   | 9 (3.2%)      | 14 (5.1%)     |      |
| I-hour acute physiology score (SD) | 36 (19.5) | 38.5 (20.1) | 0.14 |
| 24-hour acute physiology score (SD) | 62.8 (21.4) | 66 (21.5) | 0.075|
| Dialysis               |               |               | 0.203|
| Chronic                | 15 (5.3%)     | 18 (6.5%)     |      |
| New/acute              | 26 (9.1%)     | 37 (13.4%)    |      |
| Mechanical ventilation |               |               | 0.119|
| Noninvasive            | 45 (15.8%)    | 65 (23.6%)    |      |
| Invasive               | 112 (39.3%)   | 92 (33.3%)    |      |
| Both                   | 72 (25.3%)    | 65 (23.6%)    |      |
| IVC filter             | 11 (3.9%)     | 7 (2.5%)      | 0.374|
| Mechanical VTE prophylaxis device | 119 (41.7%) | 88 (31.3%) | 0.015|
| Subcutaneous heparin   | 282 (98.9%)   | 270 (97.8%)   |      |
| Subcutaneous dalteparin| 3 (1.1%)      | 6 (2.2%)      |      |

Figure 2: BMI distribution.

Our findings. In contrast, we did not show the statistically significant risk associated with BMI although this could be related to our lower-than-predicted incidence compared to our use of the PROTECT study to guide our incidence. The PROTECT study was much larger and screened for DVT prospectively with surveillance ultrasound. Additionally, the PROTECT study utilized dalteparin 5000 units daily or subcutaneous heparin 5000 units twice daily (BID). Our evaluation utilized a more aggressive SQH dosing regimen and involved few patients receiving low molecular weight heparin for chemoprophylaxis. Despite these differences, both of these studies add to the growing evidence that increased BMI and the use of vasoressors may increase the risk of VTE in critically ill patients.

The main limitations of this study are that it was retrospective and our power calculations assumed a higher
5. Conclusions

Obesity is increasing not only in the United States but across the global population. We as critical care clinicians should prepare for the potential differences this population may present in their care. VTE chemoprophylaxis is a standard of care for critically ill patients; however, prior literature points to possible shortfalls in the protection of the obese population from VTE events while undergoing ICU level of care. The thousands of dollars of additional cost to diagnose, bed, and treat a new VTE add to the importance of adequately protecting critically ill patients from this consequence [30]. In this single center retrospective review, we found a higher incidence of VTE in the BMI $\geq 30\text{kg/m}^2$ group compared to the BMI $<30\text{kg/m}^2$ group, although this did not reach statistical difference. This study highlights the need for further study of VTE prevention in the obese population, in particular whether standard dosing or altered dosing of prophylactic agents is required.

Competing Interests

The authors declare no competing interests regarding the publication of this paper.
Table 4: Characteristics of VTE patients.

| Characteristics                               | BMI < 30 kg/m² | BMI ≥ 30 kg/m² |
|-----------------------------------------------|---------------|---------------|
|                                               | N = 12        | N = 18        |
| BMI of patients with VTE (SD)                  | 25.7 (3.23)   | 39.3 (9.7)    |
| Less than or equal to 20                       | 1             | 0             |
| 20.1–25                                       | 3             | 0             |
| 25.1–29.9                                     | 8             | 0             |
| 30–34.9                                       | 0             | 9             |
| 35–39.9                                       | 0             | 3             |
| Greater than or equal to 40                    | 0             | 6             |
| Male (%)                                       | 6 (50%)       | 7 (39%)       |
| Age (SD)                                       | 61.5 (15.4)   | 63 (15.1)     |
| Primary admission Dx                           |               |               |
| Cardiovascular                                 | 0             | 3             |
| Respiratory                                    | 8             | 8             |
| Gastrointestinal                               | 0             | 3             |
| Renal                                         | 1             | 1             |
| Neurologic                                     | 1             | 0             |
| Sepsis                                        | 2             | 3             |
| Other                                         | 0             | 0             |
| Secondary admission Dx                         |               |               |
| Cardiovascular                                 | 0             | 1             |
| Respiratory                                    | 2             | 2             |
| Gastrointestinal                               | 0             | 2             |
| Renal                                         | 1             | 1             |
| Neurologic                                     | 0             | 0             |
| Sepsis                                        | 3             | 2             |
| Other                                         | 1             | 0             |
| APS, 1 hour (SD)                               | 42 (31.5)     | 39.2 (19.3)   |
| APS, 24 hours (SD)                             | 70.5 (17.6)   | 68.4 (24.2)   |
| On vasopressor anytime                         | 10            | 12            |
| Vasopressor at time of event                   | 2             | 3             |
| Norepinephrine                                 | 1             | 3             |
| Vasopressin                                    | 1             | 0             |
| Epinephrine                                    | 0             | 0             |
| Phenylephrine                                  | 1             | 0             |
| Dopamine                                       | 0             | 0             |
| Dobutamine                                     | 0             | 0             |
| Antiplatelet agent                             | 3             | 6             |
| Prior thrombosis                               | 2             | 2             |
| Sleep apnea                                    | 1             | 5             |
| Active oncologic/hematologic malignancy        | 3             | 9             |
| Noninvasive ventilation at any time prior to event | 5            | 9             |
| Noninvasive ventilation at time of event       | 0             | 2             |
| Invasive ventilation at any time prior to event | 10            | 13            |
| Invasive ventilation at time of event          | 8             | 8             |
| Dialysis                                       |               |               |
| Acute/new                                      | 3             | 6             |
| Chronic                                        | 0             | 0             |
| IVC filter                                     | 1             | 3             |
| Mechanical VTE prophylaxis documented          | 7             | 7             |
| HIT                                            | 2             | 2             |

*Same patient on all vasopressors.*
Acknowledgments

The authors would like to acknowledge and thank Dr. Adrian Garofoli for his assistance in data collection. This study was (partially) funded by a research grant from Mayo Clinic Pharmacy Services Discretionary Fund.

References

[1] K. M. Flegal, D. Carroll, B. K. Kit, and C. L. Ogden, "Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010," The Journal of the American Medical Association, vol. 307, no. 5, pp. 491–497, 2012.

[2] NIH: Overweight and Obesity Statistics, http://www.niddk.nih.gov/health-information/health-statistics/Pages/overweight-obesity-statistics.aspx.

[3] WHO, "New WHO statistics report includes good news for women's and children's health," http://www.who.int/pmnch/media/news/2012/20120516_who_statistics/en.

[4] B. L. Erstad, "Dosing of medications in morbidly obese patients in the intensive care unit setting," Intensive Care Medicine, vol. 30, no. 1, pp. 18–32, 2004.

[5] S. R. Kahn, W. Lim, A. S. Dunn et al., "Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines," Chest, vol. 141, no. 2, supplement, pp. e995S–e226S, 2012.

[6] M. K. Gould, D. A. Garcia, S. M. Wren et al., "Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines," Chest, vol. 141, no. 2, supplement, pp. e227S–e277S, 2012.

[7] W. H. Geerts, D. Bergqvist, G. F. Pineo et al., "Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)," Chest, vol. 133, supplement, no. 6, pp. 381S–453S, 2008.

[8] D. Cook, M. Crowther, M. Meade et al., "Deep venous thrombosis in medical–surgical critically ill patients: prevalence, incidence, and risk factors," Critical Care Medicine, vol. 33, no. 7, pp. 1565–1571, 2005.

[9] J. Attia, J. G. Ray, D. J. Cook, J. Douketis, J. S. Ginsberg, and W. H. Geerts, "Deep vein thrombosis and its prevention in critically ill adults," Archives of Internal Medicine, vol. 161, no. 10, pp. 1268–1279, 2001.

[10] D. J. Cook, G. Rocker, M. Meade et al., "Prophylaxis of thromboembolism in critical care (PROTECT) trial: a pilot study," Journal of Critical Care, vol. 20, no. 4, pp. 364–372, 2005.

[11] D. Cook, J. McMullin, R. Hodder et al., "Prevention and diagnosis of venous thromboembolism in critically ill patients: a Canadian survey," Critical Care, vol. 5, no. 6, pp. 336–342, 2001.

[12] F. Fraisse, L. Holzapfel, J. M. Couland et al., "Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France," American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 4, part 1, pp. 1109–1114, 2000.

[13] J. F. Cade, "High risk of the critically ill for venous thromboembolism," Critical Care Medicine, vol. 10, no. 7, pp. 448–450, 1982.

[14] S. Robinson, A. Zinck, U. L. Larsen et al., "A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial," Critical Care, vol. 17, no. 2, article R75, 2013.

[15] S. S. Cheng, K. Nordenholz, D. Matero et al., "Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition," Intensive Care Medicine, vol. 38, no. 4, pp. 642–648, 2012.

[16] S. Robinson, A. Zinck, T. Strom, T. B. Larsen, B. Rasmussen, and P. Toft, "Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial," Critical Care, vol. 14, no. 2, article R41, 2010.

[17] A. J. Mayr, M. Dünser, S. Jochberger et al., "Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin," Thrombosis Research, vol. 105, no. 3, pp. 201–204, 2002.

[18] C. Becattini, G. Agnelli, G. Manina, G. Noya, and F. Rondelli, "Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention," Surgery for Obesity and Related Diseases, vol. 8, no. 1, pp. 108–115, 2012.

[19] A. L. Brasiliero, F. Miranda Jr., J. E. M. T. Ettinger et al., "Incidence of lower limbs deep vein thrombosis after open and laparoscopic gastric bypass: a prospective study," Obesity Surgery, vol. 18, no. 1, pp. 52–57, 2008.

[20] S. A. Cotter, W. Cantrell, B. Fisher, and R. Shopnick, "Efficacy of venous thromboembolism prophylaxis in morbidly obese patients undergoing gastric bypass surgery," Obesity Surgery, vol. 15, no. 9, pp. 1316–1320, 2005.

[21] Q. H. Gonzalez, D. S. Tisher, J. J. Plata-Munoz et al., "Incidence of clinically evident deep venous thrombosis after laparoscopic Roux-en-Y gastric bypass," Surgical Endoscopy and Other Interventional Techniques, vol. 18, no. 7, pp. 1082–1084, 2004.

[22] G. G. Hamad and P. S. Chohan, "Enoxaparin for thrombo- prophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study," Obesity Surgery, vol. 15, no. 10, pp. 1368–1374, 2005.

[23] M. T. Miller and P. F. Rovito, "An approach to venous thromboembolism prophylaxis in laparoscopic Roux-en-Y gastric bypass surgery," Obesity Surgery, vol. 14, no. 6, pp. 731–737, 2004.

[24] D. A. Winegar, B. Sherif, V. Pate, and E. J. Demaria, "Venous thromboembolism after bariatric surgery performed by bariatric surgery center of excellence participants: analysis of the bariatric outcomes longitudinal database," Surgery for Obesity and Related Diseases, vol. 7, no. 2, pp. 181–188, 2011.

[25] D. J. Scholten, R. M. Hoedema, and S. E. Scholten, "A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery," Obesity Surgery, vol. 12, no. 1, pp. 19–24, 2002.

[26] K. Singh, E. R. Podolsky, S. Um et al., "Evaluating the safety and efficacy of BMI-based preoperative administration of low-molecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery," Obesity Surgery, vol. 22, no. 1, pp. 47–51, 2012.

[27] W. Lim, M. Meade, F. Lauzier et al., "Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients," Critical Care Medicine, vol. 43, no. 2, pp. 401–410, 2015.

[28] E. R. Haut, B. D. Lau, P. S. Kraus et al., "Preventability of hospital-acquired venous thromboembolism," JAMA Surgery, vol. 150, no. 9, pp. 912–915, 2015.

[29] S. J. Twigg, A. McCririck, and P. M. Sanderson, "A comparison of postmortem findings with post hoc estimated clinical diagnoses of patients who die in a United Kingdom intensive
care unit,” *Intensive Care Medicine*, vol. 27, no. 4, pp. 706–710, 2001.

[30] R. A. Fowler, N. Mittmann, W. Geerts et al., “Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients,” *The Journal of the American Medical Association*, vol. 312, no. 20, pp. 2135–2145, 2014.